Surgery to remove the tumor is usually the first treatment. It can permanently cure the condition if the tumor is completely removed.
If the tumor has spread to the liver, treatment involves destroying the local blood supply of the tumor or giving chemotherapy directly into the liver.
When the entire tumor cannot be removed, removing large portions of the tumor ("debulking") can help relieve the symptoms.
Octreotide injections are sometimes given to people with advanced carcinoid tumors that cannot be removed with surgery. Interferon is often given with octreotide to help stop tumor growth. Patients whose carcinoid tumor secretes histamine will benefit from treatment with antihistamine drugs.
People with carcinoid syndrome should avoid alcohol, large meals, and foods high in tyramine (aged cheeses, avocado, many processed foods), because they may trigger symptoms.
Some common medicines, like selective serotonin reuptake inhibitors (SSRIs), such as paroxetine (Paxil) and fluoxetine (Prozac), may make symptoms worse by increasing levels of serotonin. However, do not stop taking these medicines unless your doctor tells you to do so.
Learn more about carcinoid syndrome and get support from:
The outlook in patients with carcinoid syndrome is different from the outlook in patients who have carcinoid tumors without the syndrome.
In people with the syndrome, the tumor has usually spread to the liver, which lowers the survival rate. People with carcinoid syndrome are also more likely to have a separate cancer (second primary tumor) at the same time.
The outlook is more favorable thanks to new treatment methods, such as Sandostatin.
- Increased risk of falls and injury (from low blood pressure)
Bowel obstruction(from tumor) Gastrointestinal bleeding
- Heart valve failure
Calling your health care provider
Call for an appointment with your health care provider if you have symptoms of carcinoid syndrome.
Review Date: 09/26/2010
Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.